Choksi Laboratories holds EGM to approve convertible warrant issuance

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • EGM held on October 17, 2026, via video conferencing
  • Proposal for preferential issue of convertible warrants presented
  • Promoters and proposed allottees abstained from voting
  • Remote e-voting period ran from October 14 to October 16, 2026
powered bylight_fuzz_icon
53849195

*this image is generated using AI for illustrative purposes only.

Choksi Laboratories Limited convened an Extra Ordinary General Meeting (EGM) on October 17, 2026, to seek shareholder approval for issuing convertible warrants on a preferential basis. The meeting was conducted via video conferencing in compliance with regulatory guidelines.

The Board of Directors had previously approved the proposal for the preferential issue, subject to requisite compliances and member approval. This item was included as Special Business in the notice convening the EGM.

Voting and Participation Details

Remote e-voting was facilitated through the Central Depository Services (India) Limited platform for shareholders holding shares as of the cut-off date of October 10, 2026. The voting window opened on October 14, 2026, at 9:00 am and closed on October 16, 2026, at 5:00 pm.

A notable procedural aspect of the meeting was the abstention from voting by specific stakeholders. The Promoters and the proposed allottees in the preferential issue refrained from casting their votes on the resolution regarding the warrant issuance.

Meeting Proceedings

The meeting commenced at 12:33 pm and concluded at 12:39 pm. Mr. Sunil Choksi, Managing Director and Chairman, confirmed the presence of quorum and declared the meeting in order. Ms. Surbhi Agrawal, Practicing Company Secretary, served as the Scrutinizer to ensure a fair and transparent voting process.

All Directors, Key Managerial Personnel, and Auditors attended the virtual meeting. The Company Secretary provided an opportunity for registered shareholders to speak, though no further business was transacted before the meeting concluded with a vote of thanks.

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-4.98%+6.72%+1.20%+105.74%+21.60%0.0%

Who are the specific allottees in the preferential issue, and what strategic value do they bring to Choksi Laboratories?

How will the capital raised from the convertible warrants be allocated across R&D, capacity expansion, or debt reduction?

What are the potential dilution impacts on existing minority shareholders once the warrants are fully converted?

Choksi Laboratories shareholders approve FY26 accounts, director re-appointments

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Shareholders approved FY26 accounts with 99.98% support
  • Sunil Choksi re-appointed as MD; Himika Choksi as WTD
  • Promoter group voted 100% in favor on all three resolutions
  • Total votes polled reached 2.2 million out of 6.9 million outstanding shares
powered bylight_fuzz_icon
51270263

*this image is generated using AI for illustrative purposes only.

Choksi Laboratories shareholders approved the company’s audited financial statements for FY26 and re-appointed key directors at its 33rd Annual General Meeting held on September 18, 2026. The resolutions passed with overwhelming support, with promoter group voting reaching 100% in favor across all items.

The meeting was conducted via video conference from the company’s registered office in Indore, Madhya Pradesh. Sunil Choksi, Chairman and Managing Director, declared the meeting open after confirming quorum. The session commenced at 12:30 pm and concluded at 12:42 pm.

Voting Results

Shareholders holding shares as of September 11, 2026, were eligible to vote. A total of 3,921 shareholders were on record. Of these, 38 shareholders attended the meeting through video conferencing (four from the promoter group and 34 from the public).

Remote e-voting was facilitated through Central Depository Services (India) Limited between September 15 and September 17, 2026. Ms. Surabhi Agrawal served as the scrutinizer for the process.

Resolution-wise Breakdown

Resolution Votes Polled In Favor Against % In Favor
Adoption of FY26 Accounts 2,204,835 2,204,335 500 99.98%
Re-appointment of Sunil Choksi 2,204,835 2,204,735 100 99.99%
Re-appointment of Himika Choksi 2,204,835 2,204,735 100 99.99%

Promoter and promoter group holdings stood at 2,192,754 shares. They cast all their votes electronically, resulting in a 100% approval rate for every resolution. Public non-institutional shareholders held 4,772,509 shares, polling 12,081 votes via remote e-voting.

Key Resolutions Passed

Three primary resolutions were tabled during the session:

  • Adoption of Audited Financial Statements: Shareholders approved the balance sheet and profit and loss account for the fiscal year ended March 31, 2026, along with reports from the Board of Directors and Auditors.
  • Re-appointment of Sunil Choksi: Mr. Choksi retires by rotation under Section 152(6) of the Companies Act, 2013. Being eligible, he offered himself for re-appointment as Managing Director.
  • Re-appointment of Himika Choksi: Ms. Choksi was approved for re-appointment as a Whole-Time Director. This required a special resolution.

All directors, key managerial personnel, and auditors attended the proceedings virtually. The scrutinizer’s report confirmed that the voting process complied with Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014.

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-4.98%+6.72%+1.20%+105.74%+21.60%0.0%

What specific revenue growth or margin expansion targets did Choksi Laboratories outline for FY27 during the AGM?

How might the re-appointment of key directors influence the company's strategic roadmap for product diversification or market expansion?

Are there any planned capital expenditures or dividend policies for the upcoming fiscal year that were discussed but not explicitly detailed in the voting results?

More News on Choksi Laboratories

1 Year Returns:+21.60%